Alentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04 in Head and Neck Squamous Cell Carcinoma (HNSCC) Post published:November 16, 2023 Continue ReadingAlentis Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of ALE.C04 in Head and Neck Squamous Cell Carcinoma (HNSCC)
Alentis Therapeutics to Participate in Multiple Business Conferences in November Post published:November 2, 2023 Continue ReadingAlentis Therapeutics to Participate in Multiple Business Conferences in November
Alentis Therapeutics to Present during the American Society of Nephrology Kidney Week Post published:October 26, 2023 Continue ReadingAlentis Therapeutics to Present during the American Society of Nephrology Kidney Week
Alentis Therapeutics Appoints Lung Experts Professors Tony Mok and Steven Nathan to its Scientific Advisory Board Post published:October 5, 2023 Continue ReadingAlentis Therapeutics Appoints Lung Experts Professors Tony Mok and Steven Nathan to its Scientific Advisory Board
Alentis Therapeutics to Sponsor the 2023 European Vasculitis Society Training Course Post published:September 20, 2023 Continue ReadingAlentis Therapeutics to Sponsor the 2023 European Vasculitis Society Training Course
Alentis Therapeutics to Present at Two Upcoming Investor Conferences Post published:September 6, 2023 Continue ReadingAlentis Therapeutics to Present at Two Upcoming Investor Conferences
Alentis Therapeutics to Present at the European Respiratory Society (ERS) International Congress Post published:August 29, 2023 Continue ReadingAlentis Therapeutics to Present at the European Respiratory Society (ERS) International Congress
Alentis Therapeutics Receives FDA Fast Track Designation for ALE.C04 for the Treatment of Claudin-1 Positive HNSCC Post published:August 24, 2023 Continue ReadingAlentis Therapeutics Receives FDA Fast Track Designation for ALE.C04 for the Treatment of Claudin-1 Positive HNSCC
Alentis Therapeutics Announces First Patient Dosed in Phase 1b “FEGATO-01” Clinical Trial of ALE.F02 for the Treatment of Liver Fibrosis Post published:July 13, 2023 Continue ReadingAlentis Therapeutics Announces First Patient Dosed in Phase 1b “FEGATO-01” Clinical Trial of ALE.F02 for the Treatment of Liver Fibrosis
Alentis Therapeutics Appoints Luca Santarelli as Chairperson Post published:June 29, 2023 Continue ReadingAlentis Therapeutics Appoints Luca Santarelli as Chairperson